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The increasing incidence of breast cancer brain metastases is a major clinical problem with its associated
poor prognosis and limited treatment options. The long-acting topoisomerase-1 inhibitor, etirinotecan
pegol, was designed to preferentially accumulate in tumor tissue including brain metastases, providing
sustained cytotoxic SN38 levels. Motivated by improved survival findings from subgroup analyses from
the Phase III BEACON trial, this ongoing randomized, Phase III trial compares etirinotecan pegol to drugs
commonly used for advanced breast cancer in patients with stable, treated breast cancer brain metastases
who have been previously treated with an anthracycline, taxane and capecitabine. The primary end point
is overall survival. Secondary end points include objective response rate, progression-free survival and
time to CNS disease progression or recurrence in patients with/without CNS lesions present at study entry.
Trial registration number: NCT02915744.
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The incidence of brain metastases (BM) among women with metastatic breast cancer (MBC) has been significantly
underestimated, likely due to patients succumbing to systemic progression prior to symptomatic central nervous
system (CNS) disease [1–4]. In recent years, the incidence of BM has been estimated to be as high as 30% in
unselected patients and approaching or exceeding 35–50% in subpopulations with human epidermal growth
factor receptor 2 (HER2)-positive or ‘triple-negative’ (TNBC; estrogen and progesterone receptor negative, HER2
normal) disease [2,3,5–15]. This high incidence of BM is thought to be associated with prolonged survival secondary
to improvements in the management of systemic disease and better imaging studies, but also in large part due to
the lack of efficacy and CNS penetration of existing therapies [3–5,16,17]. Despite advances in the management of
MBC, breast cancer brain metastases (BCBM) remains a significant clinical problem, portending a poor prognosis
and leading to neurocognitive deterioration as well as interruptions in systemic disease management.
Treatment of BCBM is driven primarily by critical prognostic factors (age, tumor subtype, performance status,
number of BM and presence of extracranial metastases) and comprises varying combinations of surgery (+/-
adjuvant radiotherapy to whole brain or tumor-bed alone), whole-brain radiation therapy (WBRT; +/- a focal
boost), stereotactic radiosurgery (SRS; alone or +/- WBRT) and systemic therapies (chemotherapy or targeted
therapy, either separately or in conjunction with other localized therapeutic approaches) [2–7,10–12,16,18–26]. The
most widely used treatment for patients with multifocal BCBM is WBRT, most notably in patients with BM that
are not amenable to surgical resection or in select populations, such as those with poor performance status or
rapidly progressing systemic disease [3,6,18]. The evolution of SRS (alone or in combination) into a safe and focal
high-dose treatment for BCBM has been demonstrated by consistent rates of local control in most series [23,27–31].
While improved intracranial control has been demonstrated, survival evidence is lacking and patients are at risk
of serious quality-of-life altering adverse effects, including significant neurocognitive impairment and decline [3–
6,11,16,18–21,23,26,30]. Careful patient selection is key as timing and appropriate use of these modalities remains
debated.
Chemotherapy has traditionally played a limited role in the management of BCBM due to formidable obstacles,
including the blood–brain barrier (BBB), with its tight junctions that limit the blood-to-brain passage of many
agents [10,16,32]. Additionally, despite the apparent structural and functional breakdown of the BBB secondary to
BM as well as RT, and the subsequent development of new permeable vasculature (blood-tumor barrier or BTB),
data indicate that the BBB and BTB remain sufficiently intact to significantly impair drug delivery (although
trastuzumab emtansine, a large monoclonal antibody drug conjugate, has been shown in case reports to result in
intracranial responses in selected patients) [33–36]. Furthermore, the BBB and BTB harbor various efflux transporters,
including P-glycoprotein and breast cancer resistance protein (BCRP), which bind many of the chemotherapeutics
approved for MBC and render them ineffective [32].
It is typically desired that BCBM be treated with systemic chemotherapy before or after RT or surgery, and
more recently as an appealing option to avoid or delay WBRT and its associated complications. However, there
are no approved chemotherapy regimens indicated for the management of BCBM, nor are there consensus-
based recommendations for the general chemotherapeutic management with reasonable level of evidence, except
for a guideline on the disease management of patients with HER2-positive breast cancer and BM published in
2014 [3,5,6,10,12,22,37,38]. Although SRS may be repeatedly administered for untreated and, in some instances,
for radiated lesions, treatment options are limited for patients with BCBM that relapse or progress after initial
surgery/RT/SRS therapeutic approaches, supported by small prospective trials reporting only modest response rates
and short durations of benefit [3,7,10,11,22,38,39]. Targeted agents alone or with chemotherapy are being explored;
however, the results have been conflicting in this heavily pretreated population [40–44]. Cross-resistance, the primary
impediment to the successful treatment of patients in the advanced disease setting, as well as overlapping and/or
cumulative toxicities, most commonly neurotoxicity and myelosuppression, also frequently preclude the use of
commonly used agents in the BCBM setting [11,45–47]. Thus, novel systemic treatment approaches are critically
needed.
Etirinotecan pegol (NKTR-102)
Etirinotecan pegol (EP; also known as NKTR-102) is a novel long-acting topoisomerase I inhibitor-polymer
conjugate engineered by attaching irinotecan molecules via a biodegradable cleavable ester-based linker to a
polyethylene glycol (PEG) polymer core. Through in vivo hydrolysis of the cleavable linker, EP was specifically
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designed to provide a slow and extended release of irinotecan and subsequently slower transformation to its main
active metabolite, SN38 (7-ethyl-10-hydroxycamptothecin), resulting in reduced maximum plasma concentrations
(C-max) yet sustained SN38 concentrations [48]. Preclinical and early clinical trials demonstrated an approximate
tenfold reduction in the C-max of SN38 after EP administration compared with administration of irinotecan
and a prolongation of the SN38 half-life to approximately 50 days, which is in contrast to the half-life of SN38
following conventional administration of irinotecan of ≤2 days [48–51]. By not overwhelming the capacity of the
carboxyl-esterase enzymes that deacetylate irinotecan to SN38, the slow release of irinotecan from EP allows for a
more efficient drug activation and resultant greater SN38 area under the concentration time-curve (AUC). This
continuous exposure to SN38 is intended to improve antitumor activity while providing a more favorable toxicity
profile.
In addition to the pharmacokinetic (PK) advantages, the EP polymer conjugate achieves selective drug targeting
by exploiting abnormalities of the tumor vasculature, a phenomenon called the enhanced permeability and retention
effect or EPR [48,52,53]. This unique phenomenon of solid tumors is based on their anatomical and pathophysiological
differences from normal tissues, namely hypervascularization, aberrant architecture, hyperpermeability and lack
of lymphatic drainage. Because EP is a large macromolecule, it penetrates the leaky vasculature within the tumor
environment more readily than normal vasculature, concentrating and trapping the drug in the tumor tissue
providing prolonged exposure of the tumor.
The ATTAIN study
Here we describe the design and rationale for ATTAIN (NCT02915744), an ongoing open-label, randomized,
multicenter, international Phase III study of EP versus treatment of physician’s choice (TPC) in patients with MBC
and stable BM. The study is funded by Nektar Therapeutics, San Francisco, CA, USA.
Background & rationale for EP in the treatment of BCBM
Preclinical & early clinical investigations
Currently, available chemotherapeutic agents distribute poorly to lesions in the brain due to difficulties penetrating
the BBB and BTB, and, because many of these chemotherapeutics are substrates of the efflux transporters expressed
at these sites [32,33]. EP is not a substrate of such efflux transporters, and as demonstrated in early clinical
investigations, tumor localization via EPR is pronounced and sustained, likely from the prolonged circulation in
plasma, resulting in high concentrations of SN38 in brain tumors [48,54,55]. In a mouse xenograft BM model, EP
exhibited preferential accumulation and generated higher SN38 concentrations in brain tissue over corresponding
plasma concentrations (170- and 30-fold, respectively) [54,55]. Analyses of brain sections assessing for drug uptake
demonstrated that the SN38 concentration in brain tissue was 100-fold greater and more prolonged subsequent to
EP administration compared with non-conjugated irinotecan administration. This prolonged SN38 brain exposure
was associated with a significant regression of established BM (size and number) and a doubling of the animals’
median survival (74 days versus 37 days, for EP and irinotecan, respectively). The efficacy observed in this preclinical
model demonstrates the ability of EP to cross the BTB, leading to preferential accumulation and retention in brain
tumor, followed by sustained and efficacious concentrations of SN38.
Additional evidence for activity in the CNS was reported from a Phase II study in patients with bevacizumab-
refractory, high-grade glioma [56]. In this open-label study, 18 patients (with a median of three prior therapies)
were diagnosed with glioblastoma multiforme; 3 of the 18 (17%) had a partial response to single-agent EP, with
two responses lasting for ≥18 months. Additionally, a Phase II trial for patients with BCBM testing iniparib and
irinotecan yielded a response rate of 12%, primarily attributed to irinotecan [57]. These data further support the
preclinical evidence for the activity of irinotecan-based drugs within the brain.
Phase III BEACON trial results
The BEACON (BrEAst Cancer Outcomes with NKTR-102; NCT01492101) trial was a Phase III, open-label,
randomized, multicenter study of EP versus TPC in patients with heavily pretreated, locally recurrent or MBC
previously treated with an anthracycline, a taxane and capecitabine [58]. Eligible patients had received a minimum
of two prior cytotoxic regimens for advanced disease and no more than five for breast cancer in any setting. The
study was designed to compare the overall survival (OS) of patients treated with EP given every 3 weeks (n = 429)
or a single-agent TPC (n = 423), a control arm that allowed investigators to choose one of seven commonly used
cytotoxic drugs (eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel or nab-paclitaxel) administered
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Figure 1. Kaplan-Meier plot of overall survival for patients with stable, treated brain metastases in the BEACON Phase III trial.
EP: Etirinotecan pegol; HR: Hazard ratio; OS: Overall survival; TPC: Treatment of physician’s choice.
Created using data from Shah et al. [54].
according to local practice. Based on the preclinical data suggesting benefit, patients with a history of stable treated
BM were eligible for inclusion and were specified as a subgroup of interest in the analysis plan prior to the final
analysis of the trial. Ninety percent of the patients enrolled in the BEACON study had HER2-negative disease.
Patients in both treatment groups received a median of three treatment cycles. In the overall study population, EP
was associated with a 2.1-month median OS benefit over TPC (12.4 vs 10.3 months; p = 0.084); the hazard ratio
(HR) of 0.87 (95% CI, 0.747 to 1.019) missed statistical significance. However, EP was associated with statistically
significant survival improvements (p < 0.05) relative to TPC in important, prospectively defined subgroups with
poor prognoses, including patients with liver metastases at baseline (median OS 10.9 vs 8.3 months, respectively;
HR 0.73) and those with stable, pretreated BM at study entry as described below.
BM subgroup analysis
A total of 67 patients with a history of BM were randomized in the BEACON study. Eligibility criteria required
previous treatment with surgical resection, WBRT and/or stereotactic radiation, use of corticosteroids for BM
discontinued for ≥3 weeks prior to randomization, and that signs or symptoms of BM were stable for ≥28 days
prior to randomization. No known progression of BM (as assessed by Response Evaluation Criteria in Solid Tumors
[RECIST]) was permitted, and patients with leptomeningeal disease or meningeal carcinomatosis were excluded.
In the primary survival analysis, 60 deaths occurred in the BCBM subgroup (EP, 31 [86%]; TPC, 29 [94%]). The
prespecified BCBM subgroup analyses demonstrated a significant improvement in survival with a doubling of OS
for patients receiving EP (10 months) versus TPC (4.8 months) [59]. This reduction in death resulted in a HR of
0.51 (95% CI: 0.304–0.858; p < 0.01) (Figure 1). The median OS of 4.8 months for patients with BCBM treated
with TPC was consistent with reported median OS from previously published clinical studies in this setting, with
OS ranges of 5.0 to 6.4 months [39]. EP was also associated with improvements in 6- and 12-month survival rates;
corresponding to 72.2 and 45.2% for EP and TPC, respectively, and 44.4 and 19.4%, respectively (Figure 1).
Median progression-free survival (PFS) was 3.1 months for EP and 2.7 months for TPC (HR: 0.840; 95% CI:
0.492–1.433; p = 0.52). In patients with measurable systemic disease, partial responses were observed in 5 of 32
(15.6%) patients treated with EP and 1 of 27 (3.7%) patients on TPC; there were no complete responses in either
treatment group.
The survival trends favoring EP over TPC were also observed (post hoc) in 37 patients with radiographic evidence
of brain lesions at baseline. Median OS for this subgroup was 13.2 months (95% CI: 8.6–19.6) for EP (n = 19)
and 5.8 months (95% CI: 3.5–8.6) for TPC (n = 18). In order to correct for potential imbalances between the
groups, the BEACON investigators undertook a post hoc evaluation utilizing the Graded Prognostic Assessment
(GPA) Index, an assessment tool that assigns scores for significant prognostic indices of Karnofsky performance
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Figure 2. Study design.
†The agent must be available at the treating institution.
BCBM: Breast cancer brain metastases; ECOG: Eastern Cooperative Oncology Group; HER2: Human epidermal growth factor receptor 2;
HR: Hormone receptor; PD: Progressive disease; PS: Performance status; q21d: Every 21 days; TNBC: Triple-negative breast cancer; TPC:
Treatment of physician’s choice.
score (KPS), tumor subtype and age that was developed to predict prognosis in patients with newly diagnosed
BM [24,25]. In these analyses, treatment with EP was associated with improved OS for patients in both better and
worse prognosis groups; the HR for OS of the 67 patients after adjusting for the two GPA groups was 0.467
favoring EP, reinforcing the activity of EP in BCBM patients.
Safety of EP
The nature, scope and severity of the safety findings to date with EP have been clinically manageable and consistent.
In the BEACON trial [58,60] and the BCBM subgroup [59], EP demonstrated a significantly lower rate of grade 3 or
greater and dose-limiting/quality of life-reducing toxicities (notably neuropathy, myelosuppression and alopecia).
EP was associated with more gastrointestinal toxicities, including diarrhea, with grade 3 diarrhea reported as
9.6 versus 1% in the entire BEACON population and 5.9 versus 3.7% in the BCBM subgroup for EP and TPC,
respectively; no grade 4 diarrhea was reported.
In the analysis of patient-reported outcomes in the BEACON trial [61], there was evidence of benefit associated
with EP compared with current standard of care agents in multiple Health-Related Quality of Life measurements,
including global health status and physical functioning, despite worse gastrointestinal symptoms (e.g. diarrhea).
Differences were seen favoring EP up to 32 weeks for global health status (GHS) and physical functioning scales
(p < 0.02); numerical improvement was reported in other functional scales.
The encouraging survival findings, the favorable safety profile and quality of life findings among the BEACON
study patients with BCBM together with the Phase II evidence of single-agent activity in recurrent high-grade
primary brain tumors, provides strong rationale and justification for the further exploration of EP in patients with
BCBM previously treated with an anthracycline, taxane and capecitabine.
ATTAIN study design
Study design & objectives
ATTAIN will randomize up to 220 patients to EP (145 mg/m2 every 21 days [q21d] as a 90-min intravenous
[IV] infusion on day 1 of each treatment cycle) or to TPC consisting of single-agent IV chemotherapy limited
to one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel or nab-
paclitaxel (administered [every 21 to 28 days] per standard of care) (Figure 2). Treatment will continue until
disease progression per RECIST version 1.1 [62] and/or Response Assessment in Neuro-Oncology Brain Metastases
(RANO-BM) criteria [63], unacceptable toxicity, patient withdrawal, investigator decision, loss to follow-up, death,
noncompliance, pregnancy or study termination by the sponsor. Crossover to EP is not allowed.
The investigator must determine at screening which TPC regimen will be offered to the patient as part of the
informed consent process and provide that choice to the independent contract research organization responsible
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Box 1. ATTAIN trial objectives.
Primary objective
• To compare OS of patients who receive EP with OS of patients who receive TPC selected from the following list of
seven single-agent intravenous therapies: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel or
nab-paclitaxel
Secondary objectives
• To compare the ORR between the two treatments; assessment of tumor outside the CNS will use
• RECIST (version 1.1) criteria; assessment of CNS metastases will use RANO-BM criteria
• To compare PFS of the two treatments; assessment of tumor outside the CNS will use RECIST (version 1.1) criteria;
assessment of CNS metastases will use RANO-BM
• To compare the CBR of the two treatments (i.e., the proportion of patients having CR, PR, or SD for at least
4 months); CBR for peripheral lesions and for CNS lesions will be separately described
• To compare DoR of the two treatments; peripheral lesions and CNS lesions will be separately described
• To compare the time to CNS disease progression in those patients with CNS lesions present at study entry
• To compare the time to CNS recurrence in those patients with without CNS lesions present at study entry
• To compare the incidence and cumulative frequency of WBRT after date of randomization
• To compare the time-to-WBRT in those patients who received WBRT after the date of randomization
• To evaluate the safety profiles of EP and TPC (eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel,
docetaxel, or nab-paclitaxel)
• To compare HRQoL between the two treatments using the EORTC QLQ C30 with the BN-20 questionnaire, EQ
5D-5L™ and the BFI
• To evaluate PK data (in patients randomized to EP only)
• To correlate presence of reduced function UGT1A1 variants with EP safety (in patients randomized to EP only)
• To evaluate the pharmacoeconomic implications of EP therapy using selected measures of health care utilization
• To evaluate the magnitude of clinical benefit using ESMO-MCBS
Exploratory objectives
• To identify biomarkers that correlate with ORR, PFS and OS
BFI: Brief Fatigue Inventory: BN-20: Brain neoplasms 20-question subscale; CBR: Clinical benefit rate; CNS: Central nervous system;
CR: Complete response; DoR: Duration of response; EORTC QLQ C30: European Organisation for Research and Treatment of Cancer
Quality of Life Core 30 questionnaire; EP: Etirinotecan pegol; EQ 5D-5LTM: EuroQol 5D questionnaire; ESMO-MCBS: European
Society for Medical Oncology magnitude of clinical benefit scale; HRQoL: Health-related quality of life; ORR: Objective response
rate; OS: Overall survival; PK: Pharmacokinetic; PR: Partial response; PFS: Progression-free survival; RANO-BM: Response Assessment
in Neuro-Oncology Brain Metastases; RECIST: Response Evaluation Criteria in Solid Tumors; SD: Stable disease; TPC: Treatment of
physician’s choice; UGT1A1; Uridine diphosphate-glucuronosyl transferase 1A1; WBRT: Whole brain radiation therapy.
for creating and administering the randomization scheme. Patients will then be randomized centrally (1:1) via an
interactive response system to EP or the registered TPC regimen for the individual patient. Patients will be stratified
by geographic region (US versus rest of world), tumor receptor status (TNBC versus HER2-positive versus hormone
receptor-positive/HER2-negative) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs
1).
The primary objective is to compare OS between the two treatment groups. Secondary and exploratory objectives
are listed in Box 1 and include objective response rate [outside the CNS (ORR) and in BM (ORR-BM)], PFS
(outside the CNS, in BM [PFS-BM] and CNS plus peripheral [PFS-overall]), clinical benefit rate (CBR), duration
of response (DoR), time to CNS progression in patients with CNS lesions present at study entry, time to CNS
recurrence in patients without CNS lesions present at study entry, incidence and cumulative frequency of WBRT,
time-to-WBRT in those patients who received WBRT after randomization, PK, correlation of reduced function
UGT1A1 variants with EP safety, pharmacoeconomic implications, toxicity and health-related quality of life
(HRQoL).
Eligibility criteria
Key eligibility criteria are listed in Supplementary Table 1 and include patients willing and able to comply with the
protocol and provide written informed consent prior to study-specific screening procedures, are female or male,
age ≥18 years, and have histologically confirmed carcinoma of the breast (either primary or metastatic lesion) for
which single-agent cytotoxic chemotherapy is indicated. Patients may have either measurable or non-measurable
metastatic disease according to RECIST, version 1.1 butmust have a history of BM that are non-progressing and that
had been previously treated with either combination therapy (WBRT with stereotactic radiation and/or surgery)
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≥14 days prior to randomization or single agent modality (WBRT, stereotactic radiation, or surgical resection, if
combination therapy is contraindicated) ≥7 days prior to randomization. Patients must have sufficiently recovered
from local BCBM treatment with stable signs and symptoms of BM per the investigator. For patients who have
received WBRT, or stereotactic radiation and/or surgical resection ≥28 days prior to randomization, the signs
or symptoms of BM must be stable ≥28 days prior to randomization. An eligible patient may therefore have
received definitive local therapy within the 28-day screening period as long as clinically stable. Corticosteroids
may be used as long as patients are on a stable or decreasing dose for ≥7 days prior to randomization. Prior
systemic therapy (administered in the neoadjuvant, adjuvant and/or metastatic setting) must have included an
anthracycline, a taxane and capecitabine (prior anthracycline may be omitted if not medically appropriate or
contraindicated for the patient) and the last dose of chemotherapy must have been administered within 6 months
of the date of randomization. Depending on receptor status, specific mandates for previous treatment with cytotoxic
agents, hormonal therapy and/or HER2-targeted agents are required for eligibility (Supplementary Table 1). Of
note, HER2-targeted therapy must be stopped in any patient with HER2-positive disease ≥ 14 days prior to
randomization. Patients may have received an unlimited number of prior therapies for advanced breast cancer;
minimum therapy is listed in Supplementary Table 1. Patients must have an ECOG performance status of 0 or 1
with demonstration of adequate organ function. All anticancer- and radiation therapy- related toxicities must be
completely resolved or downgraded to grade 1 or less according to National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE) version 4.03, except for diarrhea, which must be completely resolved
to baseline without supportive antidiarrheal medications. Stable sensory neuropathy must be resolved to grade ≤2,
and alopecia can be any grade.
Planned sample size & study period
ATTAIN is expected to be conducted in 11 countries in three regions. Recruitment is ongoing with a planned
accrual of up to 220 patients. The interim analysis for OS (in which the final number of projected events will be
estimated) is anticipated to occur in the second half of 2019. Depending on the number of OS events required
for the final analysis, the timing of the final analysis is currently expected to occur sometime between mid-2020 to
early 2021.
Efficacy & safety evaluation
Clinical laboratory tests will be performed by a central laboratory and used to determine eligibility and treatment
decisions; in situations where central laboratory results are not available, the Medical Monitor may approve use of a
local laboratory. Demographics and baseline disease characteristics are collected at the screening visit, together with
a physical examination, vital signs, bodyweight, medical history, complete blood count (CBC) with differential,
serum chemistry, urinalysis, prothrombin time, tumor receptor status and a detailed history of prior cancer therapies,
surgeries and radiotherapy. A serum pregnancy test is required at screening, ≤5 days prior to each cycle and at the
end-of-treatment (EOT) visit.
Tumor assessments will be performed at screening, every 8 weeks (±7 days) through week 24 and every 12 weeks
(±7 days) thereafter until documented disease progression (PD) or death. To ensure that both groups are assessed
for progression in a similar manner, tumor assessments will be obtained at this interval, regardless of delays in
chemotherapy due to toxicity. The same method of assessment and technique for acquisition of tumor assessment
data must be used to characterize each identified and reported lesion at each measurement. All patients must have
tumor assessments performed at the participating study center or a radiology facility associated with the site. Tumor
measurements will be evaluated locally and centrally per RECIST and RANO-BM criteria for non-CNS and CNS
disease, respectively. All tumor imaging (head, chest, abdomen and other as appropriate) and digital photography
must be forwarded to a central imaging facility to permit blinded independent review (local assessment will be used
for patient management and continue until PD).
The safety assessments include CBC with differential, serum chemistry, vital signs and symptom-directed
physical exam ≤5 days prior to each cycle and EOT. Treatment decisions require results from the following tests:
hemoglobin, absolute neutrophil count (ANC) and platelets. In addition, patients randomized to EP require
testing for electrolytes (bicarbonate/CO2), calcium, chloride, potassium, sodium and serum creatinine. Additional
requirements for TPC patients should follow institutional guidelines. Dose delays, reductions and discontinuations
due to adverse events (AEs) are defined in the protocol for EP and made according to the prescribing information
or local practice guidelines for TPC. Patients randomized to EP will receive loperamide for treatment of diarrhea
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and/or prophylaxis (at the discretion of the investigator and/or patient preference in the absence of constipation
starting with cycle 2 to mitigate the risk for late-onset diarrhea). Use of growth factor support in the setting of
neutropenia is permitted and must follow American Society of Clinical Oncology (ASCO) guidelines, European
Society for Medical Oncology (ESMO) guidelines, or standard of care at the local institution. Other supportive
care and permitted and/or prohibited concomitant treatments are listed in Supplementary Table 2.
All patients will complete HRQoL assessments, consisting of the European Organisation for Research and
Treatment of Cancer (EORTC; version 3.0) Quality of Life Core 30 (QLQ-C30) with the brain neoplasms 20-
question subscale (BN-20) questionnaire, the EuroQol 5D (EQ 5D 5L™) questionnaire, and the Brief Fatigue
Inventory (BFI) on day 1 prior to infusion for each cycle and at EOT. If possible, patients should complete the
questionnaire in the same setting each time. For those patients who consent, serial blood samples for biomarker
analysis will be obtained prior to cycle 1 dosing, prior to cycle 2 dosing and at the EOT visit; analysis will consist of
cell-free circulating tumor DNA using next-generation sequencing to correlate with efficacy. Additionally, patients
randomized to EP will be tested for the following: presence of UGT1A1 gene alteration (cycle 1, day 1); PK
analyses of EP, irinotecan and its metabolites SN38, SN38-glucuronide and 7-ethyl-10-(4-N-(5-aminopentanoic
acid)-1-piperidine) carbonyloxycamptothecin (APC; prior to each dose); and, for those patients who consent,
PEG-antibody measurements in blood (prior to cycle 1, prior to cycle 2 and EOT).
After discontinuation of therapy, all patients except those who withdraw consent will be followed (by contact via
phone, clinic visit, or chart views) at least every 12 weeks (± 2 weeks) until death. If allowed by country regulatory
authorities and consented to by the patient, study personnel may use public records to check for mortality for any
patient considered lost to follow-up and for patients who withdraw consent for follow-up contact. Data will be
collected on subsequent anticancer therapies in both treatment groups from the time patients come off the study
treatment until the time of primary data analysis for OS.
Statistical considerations
The study uses an adaptive design powered for detecting superiority of EP compared with TPC for the primary
efficacy end point of OS. The number of death events needed to provide 80% conditional power for the final
analysis will be determined at an interim analysis when approximately 82 death events are available using the
promising zone adaptive method [64]. Two-sided α of 0.001 will be used to test efficacy at the interim analysis.
The minimum and maximum number of death events for the final analysis will be 106 and 191, respectively. The
maximum (191) death events will be sufficient to demonstrate statistical significance for any observed hazard ratio
of 0.75 or better, which corresponds to a median difference of approximately 2 months if the median OS for TPC
is 6 months and the proportional hazard model assumption is approximately met. If OS does not reach statistical
significance, event size needed for the final OS analysis will be determined based on conditional power per the
adaptation rules described in the Data Monitoring Committee (DMC) charter.
The main efficacy analyses for the primary and secondary end points (except ORR and DoR) will be performed
in the intention-to-treat (ITT) population (i.e., all randomized patients). The secondary end point analyses of
ORR and DoR will utilize the Response Evaluable Population, which consists of all patients who are randomized
in the study with measurable disease in the periphery by RECIST at baseline (as determined by the investigator).
Safety analyses will be conducted in all patients who are randomized and receive at least one dose (or partial dose)
of study drug (EP or TPC). The PK and biomarker populations will be those patients with sufficient data to permit
analysis.
The primary analysis of OS will be the Cui, Hung andWang (CHW) test with prespecified weights [65] to ensure
type I error control and the conventional test with equal weights for every patient will be conducted as a sensitivity
analysis. The hazard ratio (EP/TPC) and its 95% CI will be calculated using a Cox regression model adjusting
for geographic region, tumor receptor status and ECOG. The two-sided significance level for superiority at final
analysis of OS will be 0.0499. If more than 10% of the study population (i.e.,>22 patients) received local treatment
for CNS lesions (SRS, WBRT or surgery) during the study, the proportion of patients who received treatment for
CNS lesions will be compared between treatment groups using Fisher’s exact test. The impact of treatment for
CNS lesions on OS will be evaluated using a Cox regression model comparing patients who received treatment for
CNS lesions with those who did not. Additional secondary efficacy analyses will be undertaken, including (1) the
difference in survival outcome depending on prior radiotherapy (SRS vs WBRT); (2) the extent of tumor burden
at study entry (two or fewer versus three or more sites of disease); (3) the impact of liver metastases; and (4) the
impact of removal of all patients selecting ixabepilone as the TPC agent.
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Secondary end points (PFS, ORR, CBR and DoR) will be assessed by the investigator as well as by independent
central review. Analysis for secondary end points will not include any adjustment for multiplicity. Statistical tests
will be two-sided with a type I error rate of 0.05. Progression-free survival (PFS-outside the CNS, PFS-BM and
PFS-overall) will be compared with a two-sided, log-rank test with the same stratification factors that were used
for randomization. Two sensitivity analyses of PFS (outside the CNS) will be performed based on the censoring
criteria with considerations of informative censoring as described in the statistical analysis plan. Kaplan–Meier
median PFS times and their 95% CI, as well as PFS curves, will be summarized by treatment group. The hazard
ratio (EP/TPC) and its 95% CI will be calculated using a Cox regression model adjusting for geographic region,
tumor receptor status, and baseline ECOG status. The analysis of ORR will be performed using Fisher’s exact
test. Clinical benefit rate (defined as CR, PR or SD ≥4 months to reflect shorter life expectancy of the BM
population) will be compared between the treatment groups using a Cochran Mantel–Haenszel test stratified by
the randomization factors. Clopper Pearson exact two-sided 95% confidence limits will be calculated in determining
the proportion of patients with ORR and CBR in each treatment group. Additionally, the magnitude of clinical
benefit of EP will be assessed by the ESMO-magnitude of clinical benefit scale (ESMO-MCBS, version 1.0); this
information will be summarized and applied to comparative outcome studies evaluating the relative benefit of
treatments using outcomes of survival, quality of life, surrogate outcomes for survival, or treatment toxicity in solid
cancers. Kaplan–Meier median DoR curves will be summarized by treatment group. DoR will be calculated based
on the central imaging facility assessment of response and progression, as well as the investigator’s assessment of
response and progression. Incidence and frequency of WBRT, as well as time to WBRT, will be compared and
summarized by treatment group. Summary statistics of absolute scores at each assessment point and changes from
baseline will be calculated by treatment group for HRQoL measures. Changes from baseline will be compared
between treatment groups using Repeated Measures Linear Mixed Effects and Generalized Linear Mixed Models
Analyses. The safety analysis will be summarized by treatment group (EP and TPC) and further tabulated for
each TPC drug. Additional safety analyses will be undertaken to investigate: (1) diarrhea, neutropenia, neuropathy
and hypersensitivity reactions; (2) pulmonary toxicity including pneumonitis and interstitial lung disease; and,
(3) the impact of prophylactic loperamide on the management of diarrhea. All additional analyses (laboratory, PK,
UGT1A1 mutation, PEG-antibodies and biomarker) will be summarized with descriptive statistics; exploratory
analyses will be undertaken to correlate selected biomarkers as well as the appearance of PEG-antibodies with ORR,
PFS and OS.
Conclusion
There remains a critical need for therapeutic interventions that prolong patient survival and maintain or improve
quality of life of patients with BCBM, in particular, using agents that are effective against both CNS and systemic
disease. The lack of consensus regarding treatment and the lack of robust data supporting current clinical practices
demonstrate the need for more controlled trials in this setting. Etirinotecan pegol (EP) is a next-generation,
long-acting topoisomerase-1 inhibitor engineered to penetrate into the brain, provide sustained anti-tumor activity
(systemically and within the CNS) and reduce systemic toxicities. The ATTAIN trial will compare the survival of
patients receiving EP to that of standard of care agents in the treatment of patients with MBC and stable BM. The
trial is a registration trial, which is currently actively recruiting eligible patients. If ATTAIN meets its primary end
point, EP treatment will establish a new and much needed therapeutic option for patients with BCBM.
Executive Summary
Breast cancer brain metastases
• Breast cancer brain metastases (BCBM) remain a challenging consequence of advanced disease with cumulative
incidence rates approaching or exceeding 35–50%, particularly in high-risk populations.
• The development of BCBM is associated with a poor prognosis and detrimental effects on quality of life.
• Treatment options for patients with BCBM following prior local surgery and/or radiotherapy remain limited with
existing chemotherapy hindered by poor penetration and distribution into the central nervous system.
• As deemed a critical unmet medical need, there is increasing optimism and interest in exploring novel treatments
for this challenging clinical problem.
Etirinotecan pegol (also called NKTR-102)
• Etirinotecan pegol (EP) is a next-generation, long-acting topoisomerase-1 inhibitor engineered to produce
sustained exposure to irinotecan and its active metabolite SN38.
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• A mouse xenograft model of BCBM demonstrated preferential accumulation of EP in brain tumors, a decrease in
both tumor burden and lesion size and extended survival times compared with conventional irinotecan.
• Etirinotecan pegol avoids P-glycoprotein and BCRP/ABCG2-mediated efflux, providing a potential added benefit
for uptake in brain lesions.
• In a prespecified subgroup analysis of the randomized Phase III BEACON trial, EP prolonged survival in patients
with breast cancer and stable brain metastases (BM) compared with commonly used drugs for the treatment of
advanced breast cancer.
The ATTAIN trial
• ATTAIN is a randomized Phase III trial of etirinotecan pegol (EP) versus treatment of physician’s choice (TPC) in
patients with MBC who have stable BM.
• Primary end point is overall survival.
• Key secondary end points include objective response rate, clinical benefit rate, duration of response and
progression-free survival (assessed by local investigator and independent central review); additionally, review
of central nervous system (CNS) lesions will be performed using RANO-BM guidelines [63].
• Other key secondary end points include time to CNS disease progression in patients with CNS lesions present at
study entry, time to CNS recurrence in patients without CNS lesions present at study entry, toxicity, magnitude
of clinical benefit assessed by the European Society for Medical Oncology magnitude of clinical benefit scale
(ESMO-MCBS, v1.0), incidence and cumulative frequency of WBRT, time-to-WBRT in those patients who
received WBRT and health-related quality of life.
• Eligibility includes patients with historically-confirmed breast cancer, either measurable or nonmeasurable
metastatic disease, stable treated (whole-brain or stereotactic radiation and/or surgical resection) brain
metastases, prior treatment with an anthracycline (unless not medically appropriate or contraindicated), a taxane
and capecitabine administered in the neoadjuvant, adjuvant and/or metastatic setting (last dose of
chemotherapy must have been administered within 6 months of randomization), and an Eastern Cooperative
Oncology Group (ECOG) performance status of 0 or 1.
• Depending on receptor status, 1 or 2 prior cytotoxic regimens are required prior to enrollment in this trial;
hormonal and/or human epidermal growth factor receptor 2 (HER2)-targeted agents may be required (minimum
requirements for number of prior regimens may be found in Supplementary Table 1).
• This study will randomize patients 1:1 to either etirinotecan pegol 145 mg/m2 as a 90-minute intravenous (IV)
infusion on day 1 of a 21-day cycle or to TPC (administered per standard of care) and stratified based on
geographic region, tumor receptor status and ECOG status.
• Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7
agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel or nab-paclitaxel (doublet therapy,
including trastuzumab-based doublets) are not permitted.
• The proposed sample size of 220 patients provides 80% power to detect a HR of 0.75 or better, corresponding to
a 2-month increase in survival favoring etirinotecan pegol at a two-sided significance level of 0.05.
• This trial is expected to be conducted in 11 countries in 3 regions; for participating trial sites, please visit:
https://clinicaltrials.gov and search NCT02915744.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website. An infographic also accompanies this
paper at the end of the references section. To download the infographic that accompanies this paper, please visit the journal
website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2019-0180
Open access
This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/4.0/
Financial & competing interests disclosure
Debu Tripathy receives institutional research funding from Novartis, consulting fees from Pfizer and Novartis, and serves in an
unpaid member of the Scientific Advisory Board for Puma Biotechnology.
Sara M Tolaney receives institutional research funding from Novartis, Genentech, Eli Lilly, Pfizer, Merck, Exelixis, Eisai, Bristol
Meyers Squibb, AstraZeneca, Cyclacel, Immunomedics, Odenate, and Nektar Dr Tolaney has served as an advisor/consultant to
Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Tesaro, and Nanostring.
Andrew D Seidman receives institutional research funding from Novartis, Odonate, and Nektar. Dr Seidman has served as an
advisor/consultant to Genomic Health, Novartis, Eli Lilly, Pfizer, AstraZeneca, Eisai, Puma, and Genentech.
Carey Anders receives researching funding from Novartis, Merrimack, PUMA, Lily, Merck, Seattle Genetics, Nektar, Tesaro, and
G1-Therapeutics. Dr. Anders has served in an uncompensated advisory role for Merck (Start 6/2018–6/2023), Novartis, Merrimack,
10.2217/fon-2019-0180 Future Oncol. (Epub ahead of print) future science group
ATTAIN phase 3 trial of etirinotecan pegol in MBC Clinical Trial Protocol
Eli Lilly, Nektar, and Seattle Genetics as well as a compensated advisory role for PUMA (9/2018–9/2019), Genentech (1/2019–
present), Eisai (1/2019–present), and IPSEN (2/2019–present). She also received royalties from UpToDate, Jones and Bartlett.
Nuhad Ibrahim receives research funding from Nektar Therapeutics. He also serves on the advisory board for Ipsen and Im-
munogenetics.
Hope S Rugo receives research support for clinical trials through the University of California from: Pfizer, Merck, Novartis,
Lilly, Genentech, OBI, Odonate, Daiichi, Eisai, Seattle Genetics and Macrogenics, and Immunomedics. She has also received travel
support from: Daiichi, Mylan, Pfizer, Amgen, Merck and Puma.
Chris Twelves has served as a consultant/advisor and received honoraria or travel funding from Roche, Daiichi Sankyo, Eisai,
Diagenode, Amcure and Pfizer over the past 5 years.
Ve´ronique Die´ras has received honoraria as a consultant and/or speaker for Roche/Genentech, Novartis, Eli Lilly, Pfizer, Eisai,
Nektar, Astellas, AbbVie, MSD, Tesaro, Daiichi Sankyo, Odonate, Seattle Genetics, and AstraZeneca. Dr Die´ras has also received
funding for travel expenses from Roche, Novartis, Pfizer, GSK, Eisai, and AstraZeneca.
Volkmar Mu¨eller has received honoraria directly from Amgen, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, Pfizer, Novartis,
Roche, Teva, and Janssen-Cilag. Dr Mu¨eller has received payment for acting as a consult or advisor for Hexal, Roche, Pfizer, Amgen,
Daiichi-Sankyo, Nektar, and Eisai. He has also received research funding from Roche, Novartis, Seattle Genetics, and Pfizer.
MA Tagliaferri is CMO at Nektar and has ownership interest (including stock, patents, etc.) in the same.
Alison L Hannah is a consultant to Nektar Therapeutics.
Javier Cortes has served as a consultant/advisor for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus,
Seattle Genetics, Daiichi Sankyo, Erytech, and Athenex. He has received honoraria from Roche, Novartis, Celgene, Eisai, Pfizer,
Samsung. Dr. Cortes has also received institutional research funding from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta
GMBH/Servier Affaires, Bayer healthcare, Eisai, F Hoffman-La Roche, Guardanth health, Merck Sharp & Dohme, Pfizer, Piqur
Therapeutics, Puma C, and Queen Mary University of London. He also owns stock in MedSIR.
The trial is sponsored by Nektar Therapeutics. This research was supported by the National Institute for Health Research Leeds
Clinical Research Facility. The authors have no other relevant affiliations or financial involvement with any organization or entity in
conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Medical writing assistance was provided by Phillips Gilmore Oncology Communications (PA, USA), funded by Nektar Therapeu-
tics.
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1. Martin AM, Cagney DN, Catalano PJ et al. Brain metastases in newly diagnosed breast cancer. A population-based study. JAMA
Oncol. 3(8), 1069–1077 (2017).
2. Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J.
Neurooncol. 127(3), 407–414 (2016).
3. Gil-Gil MJ, Martinez-Garcia M, Sierra A et al. Breast cancer brain metastases: a review of the literature and a current multidisciplinary
management guideline. Clin. Transl. Oncol. 16, 436–446 (2014).
4. Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Goncalves A. Recent trends in epidemiology of brain metastases: an overview.
Anticancer Res. 32, 4655–4662 (2012).
• Review of recent trends in brain metastases highlighting epidemiologic characteristics, rationalized use of surgical resection,
radiosurgery and whole-brain radiotherapy, and progress in the development of systemic treatments.
5. Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H. Breast cancer brain metastases: biology and new clinical perspectives. Breast
Cancer Res. 18(1), 8 (2016).
6. Zagar TM, Van Swearingen AE, Kaidar-Person O, Ewend MG, Anders CK. Multidisciplinary management of breast cancer brain
metastases. Oncology (Williston Park). 30(10), 923–933 (2016).
7. Leone JP, Lee AV, Brufsky AM. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent
craniotomy. Cancer Med. 4(7), 989–994 (2015).
8. Soni A, Ren Z, Hameed O et al. Breast cancer subtypes predispose the site of distant metastases. Am. J. Clin. Pathol. 143(4), 471–478
(2015).
9. Aversa C, Rossi V, Geuna E et al.Metastatic breast cancer subtypes and central nervous system metastases. Breast. 23(5), 623–628 (2014).
10. Lim E, Lin NU. Updates on the management of breast cancer brain metastases. Oncology (Williston Park). 28(7), 572–578 (2014).
11. Anderson A, Choy C, Neman J, Duenas MJ, Jandial R, Somlo G. Metastatic breast cancer to the brain: a clinical primer for translational
investigation. In: Madame Curie Bioscience Database. Landes Bioscience, Austin, TX, USA (2013).
future science group 10.2217/fon-2019-0180
Clinical Trial Protocol Tripathy, Tolaney, Seidman et al.
12. Lim E, Lin NU. New insights and emerging therapies for breast cancer brain metastases. Oncology (Williston Park). 26, 652–659, 663
(2012).
13. Lin NU, Vanderplas A, Hughes M et al. Clinicopathological features, patterns of recurrence, and survival among women with
triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 118(22), 5463–5472 (2012).
14. Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28(20), 3271–3277 (2010).
15. Niwin´ska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA
RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann. Oncol. 21, 942–948 (2010).
16. Venur VA, Leone JP. Targeted therapies for brain metastases from breast cancer. Int. J. Mol. Sci. 17(9), 1543 (2016).
17. Moja L, Tagliabue L, Balduzzi S et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst. Rev. 4,
CD006243 (2012).
18. Khuntia D. Contemporary review of the management of brain metastasis with radiation. Adv. Neurosci. 2015, 1–13 (2015).
19. Leone JP, Leone BA. Breast cancer brain metastases: the last frontier. Exp. Hematol. Oncol. 4, 33 (2015).
20. Mehta M. The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients. Neuro. Oncol. 17(7), 919–923
(2015).
21. Sahgal A. Point/counterpoint: stereotactic radiosurgery without whole-brain radiation for patients with a limited number of brain
metastases: the current standard? Neuro. Oncol. 17(7), 916–918 (2015).
22. Lombardi G, Di Stefano AL, Farina P, Zagonel V, Tabouret E. Systemic treatments for brain metastases from breast cancer, non-small
cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat. Rev. 40(8), 951–959 (2014).
23. Tsao M, Xu W, Sahgal A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting
with a limited number of brain metastases. Cancer 118, 2486–2493 (2012).
24. Sperduto PW, Kased N, Roberge D et al. Summary report on the Graded Prognostic Assessment: an accurate and facile diagnosis-specific
tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 30(4), 419–425 (2012).
25. Sperduto PW, Kased N, Roberge D et al. Effect of tumor subtype on survival and the graded prognostic assessment (GPA) for patients
with breast cancer and brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 82(5), 2111–2117 (2012).
•• The data presented confirmed the effect of tumor subtype on survival and demonstrated that breast-GPA offers significantly
more predictive power than tumor subtype alone. The proposed breast-GPA index has the potential to alter clinical management
of patients with breast cancer and brain metastases through 1) individualized clinical decision making; 2) comparing trials; 3)
re-analyzing prior trials; 4) stratifying patients enrolled in future prospective trials; 5) guiding clinical trial development, and; 6)
designing treatment guidelines.
26. Niwin´ska A, Murawska M, Pogoda K. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in
patients with brain metastases. Cancer 116(18), 4238–4247 (2010).
27. Brown PD, Jaeckle K, Ballman KV et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive
function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316(4), 401–409 (2016).
28. Sahgal A, Aoyama H, Kocher M et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4
brain metastases: individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 91(4), 710–717 (2015).
29. Soon YY, Tham IW, Lim KH, Koh WY, Lu JJ. Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery
alone for brain metastases. Cochrane Database Syst. Rev. 3, CD009454 (2014).
30. Tallet AV, Azria D, Barlesi F et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual
assessment. Radiat. Oncol. 7, 77 (2012).
31. Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of
one to three cerebral metastases: results of the EORTC 22952–26001 study. J. Clin. Oncol. 29(2), 134–141 (2011).
32. Agarwal S, Hartz AMS, Elmquist WF, Bauer B. Breast cancer resistance protein and p-glycoprotein in brain cancer: two gatekeepers
team up. Curr. Pharm. Des. 17(26), 2793–2802 (2011).
33. Lockman PR, Mittapalli RK, Taskar KS et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental
brain metastases of breast cancer. Clin. Cancer Res. 16(23), 5664–5678 (2010).
34. Kalsi R, Feigenberg S, Kwok Y et al. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review.
Clin. Breast Cancer. 15(2), e163–6 (2015).
35. Bartsch R, Berghoff AS, Vogl U et al. Activity of T-DM1 in Her2-positive breast cancer metastases. Clin. Exp. Metastasis. 32(7), 729–37
(2015).
36. Keith KC, Lee Y, Ewend MG et al. Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: a case
series. Cancer Treat. Commun. 7, 43–46 (2016).
37. Ramakrishna N, Temin S, Chandarlapaty S et al. Recommendations on disease management for patients with advanced human
epidermal growth factor receptor 2 positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice
guideline. J. Clin. Oncol. 32(19), 2100–2108 (2014).
10.2217/fon-2019-0180 Future Oncol. (Epub ahead of print) future science group
ATTAIN phase 3 trial of etirinotecan pegol in MBC Clinical Trial Protocol
38. Lin NU. Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience 7, 307 (2013).
39. Arslan C, Dizdar O, Altundaq K. Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an
update. Expert Opin. Pharmacother. 15(12), 1643–1558 (2014).
40. Corte´s J, Dieras V, Ro J et al. Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive
breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-breast 3): a randomised, open-label,
multicentre, Phase 2 trial. Lancet Oncol. 16(16), 1700–1710 (2015).
41. Peereboom DM, Murphy C, Ahluwalia MS et al. Phase II trial of patupilone in patients with brain metastases from breast cancer. Neuro.
Oncol. 16(4), 579–583 (2014).
42. Freedman RA, Bullitt E, Sun L et al. A Phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain
metastases. Clin. Breast Cancer. 11(6), 376–383 (2011).
43. Hamilton E, Borges V, Conlin A et al. Efficacy results of a Phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination
with capecitabine and trastuzumab in HER2+ metastatic breast cancer, including patients with brain metastases. Presented at: 39th
Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 6–10 December 2016.
44. Borges VF, Ferrario C, Aucoin N et al. Efficacy results of a Phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with
T-DM1 in HER2+ metastatic breast cancer, including patients with brain metastases. Presented at: 52nd Annual Meeting of the American
Society of Clinical Oncology, Chicago, IL, USA, 3–9 June 2016.
45. Twelves C, Jove M, Gombos A, Awada A. Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast
cancer. Crit. Rev. Oncol. Hematol. 100, 74–87 (2016).
46. Ayoub JP, Verma Sh, Verma S. Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy. Curr.
Oncol. 19(2), 91–105 (2012).
47. Marquette C, Nabell L. Chemotherapy-resistant metastatic breast cancer. Curr. Treat. Options Oncol. 13(2), 263–275 (2012).
48. Hoch U, Staschen C-M, Johnson R, Eldon MA. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a
long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother. Pharmacol. 74(6), 1125–1137 (2014).
49. Sy SK, Sweeney TD, Ji C, Hoch U, Eldon MA. Etirinotecan pegol administration is associated with lower incidences of neutropenia
compared to irinotecan administration. Cancer Chemother. Pharmacol. 79(1), 57–67 (2017).
50. Camptosar [Package Insert]. Pfizer, NY, USA 2016. http://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=533
51. Jameson GS, Hamm JT, Weiss GJ et al. Multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics
of etirinotecan pegol in patients with refractory solid tumors. Clin. Cancer Res. 19(1), 268–278 (2013).
• First-in-human study of etirinotecan pegol that demonstrated antitumor activity in a broad spectrum of cancers, including breast
cancer. Importantly, cholinergic diarrhea associated with conventional irinotecan was not seen with etirinotecan pegol in the
dosing regimens studied.
52. Yin H, Liao L, Fang J. Enhanced permeability and retention (EPR) effect based tumor targeting: the concept, application and prospect.
JSM Clin. Oncol. Res. 2(1), 1010 (2014).
53. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol. Biol. 624, 25–37
(2010).
54. Shah N, Mohammad AS, Adkins CE et al. Etirinotecan pegol: survival advantage over standard of care drugs in a model of brain
metastases of breast cancer. Presented at: 39th Annual CTRC-AACR San Antonio Breast Cancer Symposium, TX, USA, 6–10
December 2016.
55. Adkins CE, Nounou MI, Hye T et al. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. BMC
Cancer. 15, 685 (2015).
•• Data reported demonstrated the efficacy of etirinotecan pegol in an experimental mouse model of breast cancer brain metastases
(BCBM). The authors concluded that the efficacy observed correlated with the ability of etirinotecan to cross the blood-tumor
barrier, leading to preferential accumulation and retention in brain tumor, followed by sustained efficacious concentrations of
the active metabolite, SN38. The data provide a strong rationale for the clinical use of etirinotecan pegol in patients diagnosed
with BCBM.
56. Nagpal S, Recht CK, Bertrand S et al. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high
grade glioma. J. Neurooncol. 123(2), 277–282 (2015).
•• This Phase II pilot trial of etirinotecan pegol in the treatment of heavily-pretreated (median of 3 prior therapies),
bevacizumab-refractory, high-grade glioma, which produced three partial responses in a small cohort of patients, established
foundation for further clinical investigation of the drug in brain tumors and brain metastases from SN38-sensitive primary
cancers.
57. Anders C, Deal AM, Abramson V et al. TBCRC 018: Phase II study of iniparib in combination with irinotecan to treat progressive triple
negative breast cancer brain metastases. Breast Cancer Res Treat. 146(3), 557–66 (2014).
future science group 10.2217/fon-2019-0180
Clinical Trial Protocol Tripathy, Tolaney, Seidman et al.
58. Perez EA, Awada A, O’Shaughnessy J et al. Etirinotecan pegol (NKTR-102) versus treatment of physician’s choice in women with
anthracycline-, taxane-, and capecitabine-treated advanced breast cancer: a randomised, open-label, multicentre, Phase 3 trial. Lancet
Oncol. 16(15), 1556–1568 (2015).
•• A randomized Phase III trial of etirinotecan pegol versus treatment of physician choice in women with anthracycline-, taxane-,
and capecitabine-treated advanced breast cancer that demonstrated a non-statistical 2-month survival advantage favoring
etirinotecan pegol. In pre-specified subgroups with brain and liver metastases, there was a significant OS benefit of 5.2 months
(p < 0.01) and 2.6 months (p < 0.002), respectively. Etirinotecan pegol treatment was associated with a favorable tolerability
profile and improved quality of life.
59. Corte´s J, Rugo HS, Awada A et al. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a
preplanned subgroup analysis from the randomized Phase III BEACON trial. Breast Cancer Res. Treat. 165, 329–341 (2017).
•• This preplanned subgroup analysis from the Phase III BEACON trial found that etirinotecan pegol resulted in a significant
improvement in median OS (10 vs 4.8 months; HR: 0.51; p < 0.001) compared with physician’s choice chemotherapy in patients
with breast cancer brain metastases. Etirinotecan pegol treatment was associated with fewer grade ≥3 adverse events, which was
consistent with the overall BEACON population.
60. Corte´s J, Rugo HS, Twelves C et al. Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized,
Phase 3 BEACON trial. Springerplus 5(1), 1033 (2016).
61. Twelves C, Corte´s J, O’Shaughnessy J et al. Health-related quality of life in patients with locally recurrent or metastatic breast cancer
treated with etirinotecan pegol versus treatment of physician’s choice: results from the randomised Phase III BEACON trial. Eur. J.
Cancer 76, 205–215 (2017).
62. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1).
Eur. J. Cancer 45, 228–247 (2009).
63. Lin NU, Lee EQ, Aoyama H et al. on behalf of Response Assessment in Neuro-Oncology (RANO) group. Response assessment criteria
for brain metastases: proposal from the RANO group. Lancet Oncol. 16(6), e270–278 (2015).
•• Proposed standard response and progression criteria for the assessment of brain metastases. These proposed criteria are integral
for providing uniformity of CNS assessment across clinical trials. The Response Assessment in Neuro-Oncology Brain Metastases
(RANO-BM) working group was an international, multidisciplinary effort.
64. Mehta C, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat.
Med. 30(28), 3267–3284 (2011).
65. Cui L, Hung JHM, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics 55(3), 853–857 (1999).
10.2217/fon-2019-0180 Future Oncol. (Epub ahead of print) future science group
ATTAIN phase 3 trial of etirinotecan pegol in MBC Clinical Trial Protocol
future science group 10.2217/fon-2019-0180
